BDTX Black Diamond Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1701541 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-100.0%
TTM net income YoY-305.0%
TTM EPS YoY-305.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-41.1%
ROA-32.3%
ROIC (approx.)-49.8%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets23.8%
Debt / equity0.00x
Current ratio6.92x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.76x
Accruals ratio-7.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $70.00M | $0 |
| R&D expense | $6.97M | $7.39M | $7.00M | $6.30M | $7.44M | $9.32M | $10.51M | $12.30M |
| SG&A expense | $5.15M | $4.66M | $4.26M | $3.97M | $3.54M | $4.10M | $4.96M | $5.98M |
| Operating income | -$12.12M | -$12.06M | -$11.26M | -$17.61M | -$10.98M | -$13.42M | $54.53M | -$18.27M |
| Income tax | — | — | — | — | — | $0 | $226,000 | — |
| Net income | -$10.01M | -$9.90M | -$9.04M | -$15.12M | -$8.50M | -$10.56M | $56.54M | -$15.98M |
| EBITDA | -$12.09M | -$12.03M | -$11.23M | -$17.54M | -$10.89M | -$13.33M | $54.62M | -$18.19M |
| EPS (basic) | -0.17 | -0.17 | -0.16 | — | -0.15 | -0.19 | 1.00 | — |
| EPS (diluted) | -0.17 | -0.17 | -0.16 | — | -0.15 | -0.19 | 0.98 | — |
| Weighted avg. shares (diluted) | 57.46M | 57.37M | 57.23M | — | 56.93M | 56.80M | 57.67M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $15.08M | $19.19M | $30.07M | $20.99M | $30.86M | $29.99M | $98.42M | $37.26M |
| Short-term investments | $86.95M | $91.31M | $88.19M | $107.66M | $104.64M | $112.84M | $53.98M | $62.14M |
| Current assets | $106.54M | $115.39M | $122.97M | $132.44M | $138.99M | $146.73M | $155.68M | $101.18M |
| PP&E, net | $282,000 | $310,000 | $338,000 | $365,000 | $1.13M | $1.21M | $1.30M | $1.39M |
| Total assets | $115.56M | $125.03M | $132.92M | $143.01M | $157.73M | $166.38M | $176.25M | $122.64M |
| Current liabilities | $15.40M | $15.84M | $14.53M | $15.73M | $15.54M | $16.80M | $16.85M | $20.57M |
| Total liabilities | $27.48M | $28.94M | $28.62M | $30.80M | $31.58M | $33.77M | $34.73M | $39.35M |
| Shareholders' equity | $88.08M | $96.09M | $104.30M | $112.21M | $126.15M | $132.61M | $141.52M | $83.28M |
| Shares outstanding | 57.47M | 57.45M | 57.30M | 57.14M | 56.94M | 56.89M | 56.68M | 56.64M |
| Cash flow statement | ||||||||
| Operating cash flow | -$8.34M | -$7.97M | -$10.23M | -$6.79M | -$7.85M | -$9.16M | $53.41M | -$15.05M |
| Capital expenditure | — | — | — | — | — | — | — | $0 |
| Free cash flow | — | — | — | — | — | — | — | -$15.05M |
| Investing cash flow | $4.22M | -$3.12M | $19.50M | -$2.89M | $8.59M | -$59.15M | $8.55M | $27.77M |
| Financing cash flow | $12,000 | $217,000 | -$185,000 | -$196,000 | $134,000 | -$116,000 | $32,000 | $291,000 |
| Depreciation & amortization | $28,000 | $28,000 | $27,000 | $66,000 | $86,000 | $86,000 | $87,000 | $85,000 |
| Stock-based compensation | $2.23M | $1.51M | $1.45M | $1.41M | $1.74M | $1.78M | $1.70M | $1.64M |
Free plan shows the latest 8 periods; Pro shows all 35 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.